The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

Molecular analyses of triple-negative breast cancer in the young and elderly


  • Mattias Aine
  • Ceren Boyaci
  • Johan Hartman
  • Jari Häkkinen
  • Shamik Mitra
  • Ana Bosch Campos
  • Emma Nimeus
  • Anna Ehinger
  • Johan Vallon-Christersson
  • Åke Borg
  • Johan Staaf

Summary, in English

BACKGROUND: Breast cancer in young adults has been implicated with a worse outcome. Analyses of genomic traits associated with age have been heterogenous, likely because of an incomplete accounting for underlying molecular subtypes. We aimed to resolve whether triple-negative breast cancer (TNBC) in younger versus older patients represent similar or different molecular diseases in the context of genetic and transcriptional subtypes and immune cell infiltration.

PATIENTS AND METHODS: In total, 237 patients from a reported population-based south Swedish TNBC cohort profiled by RNA sequencing and whole-genome sequencing (WGS) were included. Patients were binned in 10-year intervals. Complimentary PD-L1 and CD20 immunohistochemistry and estimation of tumor-infiltrating lymphocytes (TILs) were performed. Cases were analyzed for differences in patient outcome, genomic, transcriptional, and immune landscape features versus age at diagnosis. Additionally, 560 public WGS breast cancer profiles were used for validation.

RESULTS: Median age at diagnosis was 62 years (range 26-91). Age was not associated with invasive disease-free survival or overall survival after adjuvant chemotherapy. Among the BRCA1-deficient cases (82/237), 90% were diagnosed before the age of 70 and were predominantly of the basal-like subtype. In the full TNBC cohort, reported associations of patient age with changes in Ki67 expression, PIK3CA mutations, and a luminal androgen receptor subtype were confirmed. Within DNA repair deficiency or gene expression defined molecular subgroups, age-related alterations in, e.g., overall gene expression, immune cell marker gene expression, genetic mutational and rearrangement signatures, amount of copy number alterations, and tumor mutational burden did, however, not appear distinct. Similar non-significant associations for genetic alterations with age were obtained for other breast cancer subgroups in public WGS data. Consistent with age-related immunosenescence, TIL counts decreased linearly with patient age across different genetic TNBC subtypes.

CONCLUSIONS: Age-related alterations in TNBC, as well as breast cancer in general, need to be viewed in the context of underlying genomic phenotypes. Based on this notion, age at diagnosis alone does not appear to provide an additional layer of biological complexity above that of proposed genetic and transcriptional phenotypes of TNBC. Consequently, treatment decisions should be less influenced by age and more driven by tumor biology.


  • Division of Molecular Hematology (DMH)
  • Breast/lungcancer
  • LUCC: Lund University Cancer Centre
  • Breastcancer-genetics
  • Division of Clinical Genetics
  • The genetics of soft tissue tumors
  • Molecular therapeutics in breast cancer
  • Biomarkers and epidemiology
  • Breast cancer Proteogenomics
  • Breast Cancer Surgery
  • Pathology, Lund
  • Familial Breast Cancer
  • Research Group Lung Cancer

Publishing year





Breast cancer research : BCR





Document type

Journal article


BioMed Central (BMC)


  • Cancer and Oncology



Research group

  • The genetics of soft tissue tumors
  • Molecular therapeutics in breast cancer
  • Breast cancer Proteogenomics
  • Breast Cancer Surgery
  • Familial Breast Cancer
  • Research Group Lung Cancer


  • ISSN: 1465-5411